Printer Friendly

Statins linked to higher diabetes risk: Study.

Summary: Washington D.C. [USA], Mar 6 (ANI): A new study now finds that individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes.

Washington D.C. [USA], Mar 6 (ANI): A new study now finds that individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes.

The study was published in the British Journal of Clinical Pharmacology.

Experts examined information from 9,535 individuals older than 45 years of age who were free from diabetes at the start of the population-based Rotterdam Study and were followed up to 15 years.

When compared with participants who never used statins, those who used statins tended to have higher concentrations of serum fasting insulin and insulin resistance.

Participants who used statins had a 38 per cent higher risk of developing type 2 diabetes during the study. This risk was more prominent in individuals with impaired glucose balance and in overweight/obese individuals.

Speaking about the study, senior author Professor Bruno Stricker said, "The findings suggest that in patients who initiate statin therapy, preventive strategies such as blood sugar control and weight loss may be warranted for minimizing the risk of diabetes." (ANI)

Copyright [c] 2019 aninews.in All rights reserved. Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Asian News International
Date:Mar 6, 2019
Words:231
Previous Article:Quetta Gladiators secure top-two berth in PSL playoffs.
Next Article:File case against me, if you can: Digvijaya Singh on Pulwama 'accident' remark.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters